Meeting
2015 Genitourinary Cancers Symposium
Dual targeting of the androgen receptor and hypoxia-inducible factor-1α pathways to synergistically inhibit castrate-resistant prostate cancer.
Authors
William Douglas Figg
Genitourinary Malignancies Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD
William Douglas Figg , Elena V. Fernandez , Kelie M Reece , Ariel M Ley , Sarah M Troutman , Tristan M. Sissung , Douglas K. Price , Cindy H. Chau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 270)
DOI
10.1200/jco.2015.33.7_suppl.270
Abstract #
270
Poster Bd #
D13
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
The association between HSD3B1 genotype and steroid metabolism in normal and prostate cancer (PCa) tissue.
First Author: Hamid Emamekhoo
Poster
2017 ASCO Annual Meeting
Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer.
First Author: Neil Pegg
Poster
2014 Genitourinary Cancers Symposium
Anticancer activity of the selective CYP17A1 inhibitor, VT-464, in preclinical models of castrate-resistant prostate cancer.
First Author: Paul Toren
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.
First Author: Amy K Taylor